CFDE Data Portal | Search DLGAP1-AS5

	Label	Description
	DLGAP1-AS5 associations Collection (Entity type)	Associations for DLGAP1-AS5_associations
	DLGAP1-AS5 associations.tsv File (Entity type)	A file from IDG as part of the Harmonizome project
	DLGAP1-AS5 Gene (Entity type)	ENSG00000261520 - DLGAP1 antisense RNA 5
	GSE80098 GSE80366 progesterone 0 v 8 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE197555 trametinib A-549 NCI-H460 1 v 2 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE164529 tamoxifen 0 v 1 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE146982 metformin 0 v 1 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE161800 cisplatin A-549 0 v 2 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE146982 metformin 0 v 6 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE113369 p53 inhibition 2 v 5 human up Gene Set (Entity type)	A Gene Set from LINCS

DLGAP1-AS5 associations

Associations for DLGAP1-AS5_associations

DLGAP1-AS5 associations.tsv

A file from IDG as part of the Harmonizome project

DLGAP1-AS5

ENSG00000261520 - DLGAP1 antisense RNA 5

GSE80098 GSE80366 progesterone 0 v 8 human up

A Gene Set from LINCS

GSE197555 trametinib A-549 NCI-H460 1 v 2 human dn

A Gene Set from LINCS

GSE164529 tamoxifen 0 v 1 human up

A Gene Set from LINCS

GSE146982 metformin 0 v 1 human up

A Gene Set from LINCS

GSE161800 cisplatin A-549 0 v 2 human up

A Gene Set from LINCS

GSE146982 metformin 0 v 6 human up

A Gene Set from LINCS

GSE113369 p53 inhibition 2 v 5 human up

A Gene Set from LINCS

DISPLAY PER PAGE

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.